A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease
A Pharmacokinetic Study of Baricitinib in Subjects With Hepatic Dysfunction
Sponsor: Eli Lilly and Company
Listed as NCT01870388, this PHASE1 trial focuses on Hepatic Insufficiency and Liver Diseases and remains completed. Sponsored by Eli Lilly and Company, it has been updated 9 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE1
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Jun 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2017 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Jun 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .